Abstract P369: Impact of Enhanced External Counterpulsation on Exercise Duration in Patients With Chronic Stable Angina: A Meta-analysis

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Sachin A Shah ◽  
Bradley R Williams ◽  
Atiera Andrews-Pestana

Introduction: Enhanced External Counterpulsation (EECP) is a non-invasive Food and Drug Administration approved treatment for patients with chronic stable angina and heart failure. Typical treatment regimen comprises of 35, 1-hour sessions of synchronized compressions of the calf, thigh, and sacral muscles over a seven-week period. Exercise duration measured using an exercise tolerance test is a commonly utilized marker of worsening ischemic disease and is predictive of cardiovascular mortality. Several studies have evaluated the impact of EECP on exercise duration with conflicting results. We sought to determine the magnitude of benefit of EECP on exercise duration. Methods: A literature search was performed in MEDLINE, CINAHL, and the Cochrane database along with hand searching of relevant articles limited to those published in the English language. Studies were included for analyses if assessing patients with stable angina and reporting exercise duration data using either the Bruce or modified Bruce exercise treadmill test. Appropriate data were extracted at baseline and after completion of the full course of EECP. Studies were excluded if presenting duplicate data or using a non-Bruce protocol. A weighted mean difference from baseline along with 95% confidence interval was calculated using the DerSimonian-Laird random-effects model. Sub-group analyses, the Cochran Q statistic, and JADAD scores were utilized to assess for heterogeneity, non-combinability, and quality of published studies respectively. Publication bias was assessed using visual inspection of funnel plots and the Egger bias statistic. Results: Our search strategy identified 1117 independent studies of which 15 were included for analyses. A total of 484 individual subjects were incorporated in the primary analysis. Exercise duration improved by 55.5 seconds (95%CI 36.1 to 74.9; Cochran Q, p=0.246) from baseline. The benefits were maintained when using a fixed-effects model, excluding small studies and limiting to studies using the Bruce protocol only. While the Egger statistic showed a lack of publication bias (p=0.121), it cannot be ruled out based on visual inspection of funnel plots. Conclusion: EECP significantly increases exercise duration by 56 seconds in patients with chronic stable angina. Further studies are needed to determine the impact of EECP on long-term outcomes. The views expressed in this material are those of the authors, and do not reflect the official policy or position of the U.S. Government, the Department of Defense or the Department of the Air Force.

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Bradley Williams ◽  
Mehak Aggarwal ◽  
Cole Kiser ◽  
Krishnaswami Vijayaraghavan ◽  
Sachin A Shah

Background: Hypertension is a modifiable risk factor for ASCVD. Enhanced External Counterpulsation (EECP ® ) is an FDA-approved, non-invasive treatment modality for patients with angina and symptoms of ischemic heart failure. Various studies have demonstrated hemodynamic changes with EECP ® therapy, but the true magnitude of benefit remains unknown. We conducted a meta-analysis to assess the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) post- EECP ® therapy. Methods: A literature search across multiple databases was conducted from its inception to March 2020. Studies evaluating the impact of EECP ® in chronic stable angina patients that reported systolic and diastolic blood pressures were extracted. Human studies published in English, where patients completed 35 hours of EECP ® (administered as 1-hour sessions) were included for analysis. Studies that reported data in multiple arms were treated as individual studies. The weighted mean difference from baseline for SBP and DBP was calculated using the DerSimonian-Laird random-effects model. Statistical heterogeneity was assessed by the I 2 statistic with publication bias evaluated using the Egger bias statistic. Subgroup analyses were performed to assess for clinical heterogeneity. Results: We identified 272 articles, of which 15 unique studies (n=659) reporting data on systolic and diastolic blood pressure were included. Post- EECP ® treatment, SBP decreased by 8.9 mmHg (95% CI 4.0 to 13.7 mmHg, I 2 =87.3%) and DBP reduced by 3.6 mmHg (95% CI 2.1 to 5.0 mmHg, I 2 =38.9%). Patients with a baseline SBP 130 mmHg appear to derive greater benefit (SBP reduced by 13.0 mmHg, 95% CI 8.3 to 17.6, I 2 =70.4%) compared to patients with a baseline SBP<130 (SBP reduced by 3.2 mmHg, 95% CI 0.4 to 6.0, I 2 =25.2). The Egger bias statistic showed no publication bias for the primary endpoints (both p-values>0.33). Conclusion: EECP ® treatment reduced SBP and DBP by over 8 and 3 mmHg respectively. The pleiotropic benefits from EECP ® provide additional hypertension control in patients with chronic stable angina.


Circulation ◽  
2015 ◽  
Vol 131 (suppl_1) ◽  
Author(s):  
Tracey J McGaughey ◽  
Emily A Fletcher ◽  
Sachin A Shah

Introduction: New evidence suggests central systolic blood pressure (cSBP) is a superior predictor of adverse cardiovascular outcomes as compared to peripheral systolic blood pressure (pSBP). Additionally, augmentation index (AI) provides a surrogate assessment of vascular stiffness. We performed a meta-analysis to assess the impact of antihypertensive drug classes on cSBP and AI. METHODS: Search terms related to blood pressure and AI were used to identify relevant articles in PubMed, Cochrane Library and CINAHL limited to randomized trials in humans and publications in English. Appropriate data on cSBP, pSBP and AI were extracted along with other study characteristics. Weighted mean differences (WMD) between the pSBP and cSBP with 95% confidence intervals (CI) were calculated using the DerSimonian-Laird random-effects methodology. For AI, the WMD from baseline was determined. Further, the data was sorted by antihypertensive class (angiotensin converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium channel blockers (CCBs) and diuretics) to determine their impact on cSBP and AI. Subgroup analyses were performed to assess robustness of results by limiting to the fixed-effects model, a primary diagnosis of hypertension, and excluding studies with JADAD scores < 3. Publication bias was assessed using the Egger’s statistic and visual inspection of funnel plots. Statistical heterogeneity was assessed using the I2 statistic. RESULTS: Fifty-one and 58 studies incorporating 4381 and 3716 unique subjects were included for cSBP and AI respectively. Overall, antihypertensives reduced pSBP more than cSBP (2.52mmHg, 95%CI 1.35 to 3.69; I2 =21.9%). ACE-Is, ARBs, CCBs and diuretics reduced cSBP and pSBP in a similar manner (-2.40mmHg, 95%CI -4.89 to 0.08; 1.12mmHg, 95%CI -2.25 to 4.49; 1.01mmHg, 95%CI -2.17 to 4.19; 0.65mmHg, 95%CI -2.47 to 3.77 respectively). BBs posed a significantly greater reduction in pSBP as compared to cSBP (5.19mmHg, 95%CI 3.21 to 7.18). The change in AI from baseline was (-3.09, 95%CI -3.90 to -2.28; I2 =84.5%). A significant reduction in AI was seen with ACE-Is, ARBs, CCB and diuretics (-5.61, 95%CI -6.95 to -4.27; -5.28, 95%CI -8.61 to -1.95; -5.36, 95%CI -6.95 to -3.77; -3.24, 95%CI -5.45 to -1.03 respectively). BBs reduced AI non-significantly (-0.32, 95% CI -1.48 to 0.84). While the Egger’s statistic showed a lack of publication bias (p>0.125), it cannot be ruled out based on visual inspection of funnel plots. CONCLUSIONS: BBs are not as beneficial in reducing cSBP as opposed to ACE-Is, ARBs, CCBs and diuretics. In contrast, ACE-Is, ARBs, CCBs and diuretics significantly reduce AI, which is not evident with BB therapy. The views expressed in this material are those of the author(s), and do not reflect the official policy or position of the U.S. Government, the Department of Defense, or the Department of the Air Force.


2005 ◽  
Vol 95 (3) ◽  
pp. 394-397 ◽  
Author(s):  
Andrew D. Michaels ◽  
Gregory W. Barsness ◽  
Ozlem Soran ◽  
Sheryl F. Kelsey ◽  
Elizabeth D. Kennard ◽  
...  

2005 ◽  
Vol 150 (5) ◽  
pp. 1066-1073 ◽  
Author(s):  
Andrew D. Michaels ◽  
Ajit Raisinghani ◽  
Ozlem Soran ◽  
Paul-Andre de Lame ◽  
Michele L. Lemaire ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document